Choline as a biomarker for cell proliferation: Do the results from proton MR spectroscopy show difference between HER2/neu positive and negative breast cancers?
Open Access
- 10 June 2008
- journal article
- letter
- Published by Wiley in International Journal of Cancer
- Vol. 123 (5), 1219-1221
- https://doi.org/10.1002/ijc.23552
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- MRI features of breast cancer: a correlation study with HER-2 receptorAnnals of Oncology, 2007
- In vivo proton magnetic resonance spectroscopy of breast lesions: an updateBreast Cancer Research and Treatment, 2006
- Herceptin: mechanisms of action and resistanceCancer Letters, 2006
- The Distinctive Nature of HER2-Positive Breast CancersThe New England Journal of Medicine, 2005
- Expression Levels and Clinical-Pathological Correlations of HER2/neu in Primary and Metastatic Human Breast CancerAnnals of the New York Academy of Sciences, 2004
- Proton magnetic resonance spectroscopic imaging of human breast cancer: A preliminary studyJournal of Magnetic Resonance Imaging, 2003
- In vivo quantification of choline compounds in the breast with 1H MR spectroscopyMagnetic Resonance in Medicine, 2003
- Characterization of Lesions of the Breast with Proton MR Spectroscopy: Comparison of Carcinomas, Benign Lesions, and Phyllodes TumorsAmerican Journal of Roentgenology, 2003
- The ErbB receptors and their role in cancer progressionExperimental Cell Research, 2003
- The basic biology of HER2Annals of Oncology, 2001